Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $553.83, for a total transaction of $5,261,385.00. Following the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $22,437,314.79. This represents a 19.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Stock Down 2.2%

Shares of NASDAQ UTHR traded down $12.20 during trading on Monday, hitting $544.62. 478,808 shares of the company traded hands, compared to its average volume of 481,543. The firm has a market capitalization of $23.12 billion, a P/E ratio of 20.10, a P/E/G ratio of 1.81 and a beta of 0.57. The company has a 50-day moving average price of $566.51 and a 200-day moving average price of $516.27. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue was down 1.6% on a year-over-year basis. During the same period last year, the firm posted $6.63 EPS. Research analysts predict that United Therapeutics Corporation will post 26.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on UTHR. HC Wainwright raised their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research note on Thursday, May 7th. Bank of America raised their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Torren Management LLC acquired a new position in United Therapeutics in the 4th quarter worth $26,000. Activest Wealth Management grew its stake in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares in the last quarter. Entrust Financial LLC purchased a new stake in shares of United Therapeutics during the fourth quarter worth about $31,000. International Assets Investment Management LLC lifted its stake in shares of United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 64 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB lifted its stake in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.